Indeed. This may be the start of the upward inflection we're looking for. 386 is 2 standard deviations above the linear trend line
I would expect that the same clinical trial sites doing the DMD studies would be interested in doing this. It is in the same area of genetic muscular disease. Are the patents in place?
I'm not adept at interpreting patent issues, but the research cited in the patent in yesterday's news got my attention. The invention posits a minimum increase of 10% in dystrophin. We now know that a 10% increase from background levels of ~1% ,i.e. ~1.1% is far below the therapeutic levels required to affect muscle function. I'm reading that BMRN is not claiming that dystrophin production is the MO for improved 6mwt scores.It seems to me it would be hard to defend a patent when the embodiment doesn't do what the patent claims.
To be more specific are all morpholino compounds in the same Markush Group. And if so, then why are many companies developing morhpholino drugs without patent infringement issues. What I'm seeing is that other companies are patenting a specific combination of chemistry and genetic target and successfully defending their products. Was the ruling that came out in connection with safe harbor exemption?
The patent appears to cover all morpholinos and applications for dmd, tumors and antivirals. So I'm wondering how ISIS and others are skirting the patent.
The company cooperated by loaning shares to short, as a premium to a bond issue. Have you noticed the number of outstanding shares? That is like a having a target on your back. Every dilutive shelf is sold so that the buyer can short against the box. That's the only way they can end up owning shares at a rediculously low price. You discover where the trade is and go with the flow. GS downgraded. That's like telling the team what the next play is and when the ball will be snapped.
Thanks. Generally I stay away from vaccine companies because I don't think enough is known about the immune system to start with, but maybe that's just my ignorance. Agree on sticking to exit strategy.
Allows seller to obtain better price based on risk sharing and execution. Payment is primarily in the form of milestone payments. I see no reason why SNY or MNKD would short circuit the deal.
The obvious way is Alfred Mann. His signature strategy is obtaining financing. Watch his video on how to grow billion dollar companies. Visit the foundation web site. I think this is the ace in the hole.
trend is up. direction is set. no liquidity here and no shares to borrow (witness 20% interest).
its all about the convertible debentures. Shorts are betting on MNKD not being able to repay the loan, refinance it or obtain favorable terms. The premise is that sales will not produce income in time to retire the debt. Their goal is to depress the stock price to make a shelf offering unattractive as a means of retiring the note. Also the BOA stock loan is like walking up and down wall st with a sandwichboard that says "short mnkd"
Apparently BMRN isn't claiming that dystrophin is produced by their drug, just that it prevents disease progression. If the patent covers exon skipping, wouldn't the method in the claim have to produce dystrophin in order to be protected by their patent?
Company is reorganized under a new charter and ticker symbol with 10 shares of mnkd redeemable for 1 share in the new company. Owners of record have 30 days to redeem/exchange their shares.